The Pathophysiology, Diagnosis and Treatment of Fibromyalgia

Psychiatric Clinics of North America

Volumn 33, Issue 2, 2010, Pages 375-408

  Arnold, Lesley M ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Comorbidity; Diagnosis; Fibromyalgia; Treatment

Indexed keywords

ALPRAZOLAM; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; BENZODIAZEPINE; CITALOPRAM; CYCLOBENZAPRINE; DULOXETINE; FLUOXETINE; GABAPENTIN; IBUPROFEN; MILNACIPRAN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; OXYBATE SODIUM; PARACETAMOL; PLACEBO; PREDNISONE; PREGABALIN; SEROTONIN UPTAKE INHIBITOR; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE; ZOLPIDEM; ZOPICLONE;

ADRENERGIC ACTIVITY; AGITATION; ALTERNATIVE MEDICINE; AMBLYOPIA; ANALGESIC ACTIVITY; ANKYLOSING SPONDYLITIS; ANTICHOLINERGIC SYNDROME; ANTINOCICEPTION; ANXIETY DISORDER; ASTHENIA; ATTENTION DISTURBANCE; BACKACHE; BALANCE DISORDER; BEDTIME DOSAGE; BLURRED VISION; CLINICAL TRIAL; COGNITIVE THERAPY; COMORBIDITY; CONSTIPATION; DEPRESSION; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DISEASE DURATION; DIZZINESS; DRUG INDUCED HEADACHE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; EUPHORIA; EVENING DOSAGE; FATIGUE; FIBROMYALGIA; FLATULENCE; HEART RATE; HEREDITY; HOT FLUSH; HUMAN; INCIDENCE; INCREASED APPETITE; INSOMNIA; KINESIOTHERAPY; LABORATORY TEST; LOW DRUG DOSE; MEMORY DISORDER; MENTAL DISEASE; MONOTHERAPY; MOOD DISORDER; NAUSEA; NERVOUSNESS; ONSET AGE; PAIN THRESHOLD; PALPATION; PATIENT EDUCATION; PERIPHERAL EDEMA; PREVALENCE; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SEDATION; SEX DIFFERENCE; SIDE EFFECT; SINUSITIS; SOMNOLENCE; SPONDYLOARTHROPATHY; STRESS; SWEAT GLAND DISEASE; SWEATING; SYSTEMIC LUPUS ERYTHEMATOSUS; VISUAL ANALOG SCALE; VOMITING; WEIGHT; WEIGHT GAIN; XEROSTOMIA;

ANALGESICS; ANTIDEPRESSIVE AGENTS; COGNITIVE THERAPY; FIBROMYALGIA; HUMANS; PAIN; RISK FACTORS; SEX FACTORS; STRESS, PSYCHOLOGICAL; TREATMENT OUTCOME;

EID: 77951539192     PISSN: 0193953X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psc.2010.01.001     Document Type: Review

References (223)

1. Reynolds M.D. The development of the concept of fibrositis. J Hist Med Allied Sci 1983, 38:5-35.
2. Wolfe F., Smythe H.A., Yunus M.B., et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the multicenter criteria committee. Arthritis Rheum 1990, 33:160-172.
3. Wolfe F., Ross K., Anderson J., et al. Aspects of fibromyalgia in the general population: sex, pain threshold, and fibromyalgia symptoms. J Rheumatol 1995, 22:151-156.
4. Gracely R.H., Grant M.A.B., Giesecke T. Evoked pain measures in fibromyalgia. Best Pract Res Clin Rheumatol 2003, 17:593-609.
5. MacFarlane G.J., Croft P.R., Schollum J., et al. Widespread pain: is an improved classification possible?. J Rheumatol 1996, 23:1628-1632.
6. Pope H.G., Hudson J.I. A supplemental interview for forms of " affective spectrum disorder" Int J Psychiatry Med 1991, 21:205-232.
7. Yunus M.B., Masi A.T., Aldag J.C. Preliminary criteria for primary fibromyalgia syndrome (PFS): multivariate analysis of a consecutive series of PFS, other pain patients, and normal subjects. Clin Exp Rheumatol 1989, 7:63-69.
8. First M.B., Spitzer R.L., Gibbon M., et al. Structured interview for the DSM-IV axis I disorders-patient edition (SCID-I/P) 1995, Version 2.0, Biometrics Research Department, New York State Psychiatric Institute, New York.
9. Dwight M.M., Arnold L.M., OBrien H., et al. An open clinical trial of venlafaxine treatment of fibromyalgia. Psychosomatics 1998, 39:14-17.
10. Hudson J.I., Mangweth B., Pope H.G., et al. Family study of affective spectrum disorder. Arch Gen Psychiatry 2003, 60:170-177.
11. Arnold L.M., Hudson J.I., Hess E.V., et al. Family study of fibromyalgia. Arthritis Rheum 2004, 50:944-952.
12. Katz R.S., Wolfe F., Michaud K. Fibromyalgia diagnosis. A comparison of clinical, survey, and American College of Rheumatology Criteria. Arthritis Rheum 2006, 54:169-176.
13. White K.P., Speechley M., Harth M., et al. The London fibromyalgia epidemiology study: comparing the demographic and clinical characteristics in 100 random community cases of fibromyalgia versus controls. J Rheumatol 1999, 26:1577-1585.
14. Yunus M.B., Inanici F., Aldag J.C., et al. Fibromyalgia in men: comparison of clinical features with women. J Rheumatol 2000, 27:485-490.
15. Yunus M.B. Gender differences in fibromyalgia and other related syndromes. J Gend Specif Med 2002, 5:42-47.
16. Buskila D., Neumann L., Alhoashle A., et al. Fibromyalgia syndrome in men. Semin Arthritis Rheum 2000, 30:47-51.
17. Clauw D.J. Fibromyalgia syndrome: an update on current understanding and medical management. Rheumatol Grand Rounds 2000, 3:1-9.
18. Fitzcharles M.A., Esdaile J.M. The overdiagnosis of fibromyalgia syndrome. Am J Med 1997, 103:44-50.
19. Reilly P.A. The differential diagnosis of generalized pain. Baillieres Clin Rheumatol 1999, 13:391-401.
20. Daoud K.F., Barkhuizen A. Rheumatic mimics and selected triggers of fibromyalgia. Curr Pain Headache Rep 2002, 6:284-288.
21. Leventhal L.J., Bouali H. Fibromyalgia: 20 clinical pearls. J Musculoskel Med 2003, 20:59-65.
22. Wolfe F., Ross K., Anderson J., et al. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995, 38:19-28.
23. Makela M., Heliovaara M. Prevalence of primary fibromyalgia in the Finnish population. BMJ 1991, 303:216-219.
24. Lyddell C., Meyers O.L. The prevalence of fibromyalgia in a South African community. Scand J Rheumatol 1992, 21:8.
25. Raspe H., Baumgartner C.H. The epidemiology of fibromyalgia syndrome (FMS) in a German town. Scand J Rheumatol 1992, 21:8.
26. Prescott E., Kjoller M., Jacobsen S., et al. Fibromyalgia in the adult Danish population: I. A prevalence study. Scand J Rheumatol 1993, 22:233-237.
27. Schochat T., Croft P., Raspe H. The epidemiology of fibromyalgia. Workshop of the standing committee on Epidemiology European League Against Rheumatism (EULAR), Bad Sackingen 19-21, November 1992. Br J Rheumatol 1994, 33:783-786.
28. White K.P., Speechley M., Harth M., et al. The London fibromyalgia epidemiology study: the prevalence of fibromyalgia syndrome in London, Ontario. J Rheumatol 1999, 26:1570-1576.
29. Lindell L., Bergman S., Petersson I.F., et al. Prevalence of fibromyalgia and chronic widespread pain. Scand J Prim Health Care 2000, 18:149-153.
30. Goldenberg D.L., Simmus R.W., Geiger A., et al. High frequency of fibromyalgia patients with chronic fatigue seen in primary care practice. Arthritis Rheum 1990, 33:381-387.
31. Yunus M., Masi A.T., Calabro J.J., et al. Primary fibromyalgia (fibrositis): clinical study of 50 patients with matched normal controls. Semin Arthritis Rheum 1981, 11:151-171.
32. Yunus M.B., Masi A.T., Aldag J.C. A controlled study of primary fibromyalgia syndrome: clinical features and association with other functional syndromes. J Rheumatol 1989, 16:62-71.
33. White K.P., Harth M., Speechley M., et al. Fibromyalgia in rheumatology practice. A survey of Canadian rheumatologists. J Rheumatol 1995, 22:722-726.
34. White K.P., Harth M. Classification, epidemiology, and natural history of fibromyalgia. Curr Pain Headache Rep 2001, 5:320-329.
35. Forseth K.O., Gran J.T., Husby G. A population study of the incidence of fibromyalgia among women aged 26-55 yr. Br J Rheumatol 1997, 36:1318-1323.
36. Forseth K.O., Husby G., Gran J.T., et al. Prognostic factors for the development of fibromyalgia in women with self-reported musculoskeletal pain. A prospective study. J Rheumatol 1999, 26:2458-2467.
37. White K.P., Nielson W.R., Harth M., et al. Chronic widespread musculoskeletal pain with or without fibromyalgia: psychological distress in a representative community adult sample. J Rheumatol 2002, 29:588-594.
38. Hudson J.I., Hudson M.S., Pliner L.F., et al. Fibromyalgia and major affective disorder: a controlled phenomenology and family history study. Am J Psychiatry 1985, 142:441-446.
39. Walker E.A., Keegan D., Gardner G., et al. Psychosocial factors in fibromyalgia compared with rheumatoid arthritis: I. Psychiatric diagnoses and functional disability. Psychosom Med 1997, 59:565-571.
40. Arnold L.M., Hudson J.I., Keck P.E., et al. Comorbidity of fibromyalgia and psychiatric disorders. J Clin Psychiatry 2006, 67:1219-1225.
41. Hudson J.I., Pope H.G. The relationship between fibromyalgia and major depressive disorder. Rheum Dis Clin North Am 1996, 22:285-303.
42. Aaron L.A., Buchwald D. Chronic diffuse musculoskeletal pain, fibromyalgia, and co-morbid unexplained clinical conditions. Best Pract Res Clin Rheumatol 2003, 17:563-574.
43. Katon W., Sullivan M., Walker E. Medical symptoms without identified pathology: relationship to psychiatric disorders, childhood and adult trauma, and personality traits. Ann Intern Med 2001, 134:917-925.
44. Hudson J.I., Goldenberg D.L., Pope H.G., et al. Comorbidity of fibromyalgia with medical and psychiatric disorders. Am J Med 1992, 92:363-367.
45. Wessely S., Nimnuan C., Sharpe M. Functional somatic syndromes: one or many?. Lancet 1999, 354:936-939.
46. Sullivan P.F., Smith W., Buchwald D. Latent class analysis of symptoms associated with chronic fatigue syndrome and fibromyalgia. Psychol Med 2002, 32:881-888.
47. Wolfe F., Hawley D. Evidence of disordered symptom appraisal in fibromyalgia: increased rates of reported comorbidity and comorbidity severity. Clin Exp Rheumatol 1999, 17:297-303.
48. Wolfe F., Hawley D.J. Psychosocial factors and the fibromyalgia syndrome. Z Rheumatol 1998, 57:88-91.
49. Okifuji A., Bradshaw D.H., Olson C. Evaluating obesity in fibromyalgia: neuroendocrine biomarkers, symptoms, and functions. Clin Rheumatol 2009, 28:475-478.
50. Moldofsky H. Management of sleep disorders in fibromyalgia. Rheum Dis Clin North Am 2002, 28:353-365.
51. May K.P., West S.G., Baker M.R., et al. Sleep apnea in male patients with the fibromyalgia syndrome. Am J Med 1993, 94:505-508.
52. Gold A.R., Dipalo F., Gold M.S., et al. Inspiratory airflow dynamics during sleep in women with fibromyalgia. Sleep 2004, 27:459-466.
53. Berger A., Dukes E., Martin S., et al. Characteristics and healthcare costs of patients with fibromyalgia syndrome. Int J Clin Pract 2007, 61:1498-1508.
54. Kennedy M., Felson D.T. A prospective long-term study of fibromyalgia syndrome. Arthritis Rheum 1996, 39:682-685.
55. Wolfe F., Anderson J., Harkness D., et al. Health status and disease severity in fibromyalgia. Arthritis Rheum 1997, 40:1571-1579.
56. Ledingham J., Doherty S., Doherty M. Primary fibromyalgia syndrome-an outcome study. Br J Rheumatol 1993, 32:139-142.
57. Henriksson C.M. Longterm effects of fibromyalgia on everyday life: a study of 58 patients. Scand J Rheumatol 1994, 23:36-41.
58. Baumgartner E., Finckh A., Cedraschi C., et al. A six year prospective study of a cohort of patients with fibromyalgia. Ann Rheum Dis 2002, 61:644-645.
59. Granges G., Zilko P., Littlejohn G.O. Fibromyalgia syndrome: assessment of the severity of the condition 2 years after diagnosis. J Rheumatol 1994, 21:523-529.
60. Fitzcharles M.A., Da Costa D., Poyhia R. A study of standard care in fibromyalgia syndrome: a favorable outcome. J Rheumatol 2003, 30:154-159.
61. Goldenberg D.L. Fibromyalgia syndrome a decade later: what have we learned?. Arch Intern Med 1999, 159:777-785.
62. MacFarlane G.J., Thomas E., Papageorgiou A.C., et al. The natural history of chronic pain in the community: a better prognosis than in the clinic?. J Rheumatol 1996, 23:1617-1620.
63. Hoffman D.L., Dukes E.M. The health status burden of people with fibromyalgia: a review of studies that assessed health status with the SF-36 or the SF-12. Int J Clin Pract 2008, 62:115-126.
64. White L.A., Birnbaum H.G., Kaltenboeck A., et al. Employees with fibromyalgia: medical comorbidity, healthcare costs, and work loss. J Occup Environ Med 2008, 50:13-24.
65. White K.P., Speechley M., Harth M., et al. Comparing self-reported function and work disability in 100 community cases of fibromyalgia syndrome versus controls in London, Ontario. Arthritis Rheum 1999, 42:76-83.
66. Wolfe F., Anderson J., Harkness D., et al. Work and disability status of persons with fibromyalgia. J Rheumatol 1997, 24:1171-1178.
67. Hawley D.J., Wolfe F. Pain, disability, and pain/disability relationships in seven rheumatic disorders: a study of 1,522 patients. J Rheumatol 1991, 18:1552-1557.
68. Burckhardt C.S., Clark S.R., Bennett R.M. Fibromyalgia and quality of life: a comparative analysis. J Rheumatol 1993, 20:475-479.
69. Kaplan R.M., Schmidt S.M., Cronan T.A. Quality of well being in patients with fibromyalgia. J Rheumatol 2000, 27:785-789.
70. Epstein S.A., Kay G., Clauw D., et al. Psychiatric disorders in patients with fibromyalgia. Psychosomatics 1999, 40:57-63.
71. Pellegrino M.J., Waylonis G.W., Sommer A. Familial occurrence of primary fibromyalgia. Arch Phys Med Rehabil 1989, 70:61-63.
72. Buskila D., Neumann L., Hazanov I., et al. Familial aggregation in the fibromyalgia syndrome. Semin Arthritis Rheum 1996, 26:605-611.
73. Buskila D., Neumann L. Fibromyalgia syndrome (FM) and nonarticular tenderness in relatives of patients with FM. J Rheumatol 1997, 24:941-944.
74. Hudson J.I., Arnold L.M., Keck P.E., et al. Family study of fibromyalgia and affective spectrum disorder. Biol Psychiatry 2004, 56:884-891.
75. Bondy B., Spaeth M., Offenbaecher M., et al. The T102C polymorphism of the 5-HT2A-receptor gene in fibromyalgia. Neurobiol Dis 1999, 6:433-439.
76. Gursoy S., Erdal E., Herken H., et al. Association of T102C polymorphism of the 5-HT2A receptor gene with psychiatric status in fibromyalgia syndrome. Rheumatol Int 2001, 21:58-61.
77. Offenbaecher M., Bondy B., de Jonge S., et al. Possible association of fibromyalgia with a polymorphism in the serotonin transporter gene regulatory region. Arthritis Rheum 1999, 42:2482-2488.
78. Gursoy S. Absence of association of the serotonin transporter gene polymorphism with the mentally healthy subset of fibromyalgia patients. Clin Rheumatol 2002, 21:194-197.
79. Buskila D., Cohen H., Neumann L., et al. An association between fibromyalgia and the dopamine D4 receptor exon III repeat polymorphism and relationship to novelty seeking personality traits. Mol Psychiatry 2004, 9:730-731.
80. Zubieta J.K., Heitzeg M.M., Smith Y.R., et al. COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor. Science 2003, 299:1240-1243.
81. Gursoy S., Erdal E., Herken H., et al. Significance of catechol-O-methyltransferase gene polymorphism in fibromyalgia syndrome. Rheumatol Int 2003, 23:104-107.
82. Diatchenko L., Slade G.D., Nackley A.G., et al. Genetic basis for individual variations in pain perception and the development of a chronic pain condition. Hum Mol Genet 2005, 14:135-143.
83. van Meurs J.B., Uitterlinden A.G., Stolk L., et al. A functional polymorphism in the catechol-O-methyltransferase gene is associated with osteoarthritis-related pain. Arthritis Rheum 2009, 60:628-629.
84. Tahara T., Arisawa T., Shibata T., et al. COMT gene val158met polymorphism in patients with dyspeptic symptoms. Hepatogastroenterology 2008, 55:979-982.
85. George S.Z., Wallace M.R., Wright T.W., et al. Evidence for a biopsychosocial influence on shoulder pain: pain catastrophizing and catechol-O-methyltransferase (COMT) diplotype predict clinical pain ratings. Pain 2008, 136:53-61.
86. Harrison P.J., Tunbridge E.M. Catechol-O-methyltransferase (COMT): a gene contributing to sex differences in brain function, and to sexual dimorphism in the predisposition to psychiatric disorders. Neuropsychopharmacology 2008, 33:3037-3045.
87. Dailey P.A., Bishop G.D., Russell I.J., et al. Psychological stress and the fibrositis/fibromyalgia syndrome. J Rheumatol 1990, 17:1380-1385.
88. Anderberg U.M., Marteinsdottir I., Theorell T., et al. The impact of life events in female patients with fibromyalgia and in female healthy controls. Eur Psychiatry 2000, 15:295-301.
89. Walker E.A., Keegan D., Gardner G., et al. Psychosocial factors in fibromyalgia compared with rheumatoid arthritis: II. Sexual, physical and emotional abuse and neglect. Psychosom Med 1997, 59:572-577.
90. Imbierowicz K., Egle U.T. Childhood adversities in patients with fibromyalgia and somatoform pain disorder. Eur J Pain 2003, 7:113-119.
91. Van Houdenhove B., Neerinckx E., Lysens R., et al. Victimization in chronic fatigue syndrome and fibromyalgia in tertiary care. Psychosomatics 2001, 42:21-28.
92. Pillemer S.R., Bradley L.A., Crofford L.J., et al. The neuroscience and endocrinology of fibromyalgia. Arthritis Rheum 1997, 40:1928-1939.
93. Adler G.K., Kinsley B.T., Hurwitz S., et al. Reduced hypothalamic-pituitary and sympathoadrenal responses to hypoglycemia in women with fibromyalgia syndrome. Am J Med 1999, 106:534-543.
94. Adler G.K., Manfredsdottir V.F., Creskoff K.W. Neuroendocrine abnormalities in fibromyalgia. Curr Pain Headache Rep 2002, 6:289-298.
95. Kranzler J.D., Gendreau J.F., Rao S.G. The psychopharmacology of fibromyalgia: a drug development perspective. Psychopharmacol Bull 2002, 36:165-213.
96. Torpy D.J., Dapanicolaou D.A., Lotsikas A.J., et al. Responses of the sympathetic nervous system and the hypothalamic-pituitary-adrenal axis to interleukin-6: a pilot study in fibromyalgia. Arthritis Rheum 2000, 43:872-880.
97. Griep E.N., Boersma J.W., de Kloet E.R. Altered reactivity of the hypothalamic-pituitary-adrenal axis in the primary fibromyalgia syndrome. J Rheumatol 1993, 20:469-474.
98. Griep E.N., Boersma J.W., Lentjes E.G., et al. Function of the hypothalamic-pituitary-adrenal axis in patients with fibromyalgia and low back pain. J Rheumatol 1998, 25:1374-1381.
99. Riedel W., Kayka H., Neeck G. Secretory pattern of GH, TSH, thyroid hormones, ACTH, cortisol, FSH and LH in patients with fibromyalgia syndrome following systemic injection of the relevant hypothalamic-releasing hormones. Z Rheumatol 1998, 57:81-87.
100. Chrousos G.P., Gold P.W. The concepts of stress and stress system disorders. JAMA 1992, 267:1244-1252.
101. Clauw D.J., Chrousos G.P. Chronic pain and fatigue syndromes: overlapping clinical and neuroendocrine features and potential pathogenic mechanisms. Neuroimmunomodulation 1997, 4:134-153.
102. Demitrack M.A., Crofford L.J. Evidence for and pathophysiologic implications of hypothalamic-pituitary-adrenal axis dysregulation in fibromyalgia and chronic fatigue syndrome. Ann N Y Acad Sci 1998, 840:684-697.
103. Heim C., Ehlert U., Hellhammer D.H. The potential role of hypocortisolism in the pathophysiology of stress-related bodily disorders. Psychoneuroendocrinology 2000, 25:1-35.
104. Gold P.W., Chrousos G.P. The endocrinology of melancholic and atypical depression: relation to neurocircuitry and somatic consequences. Proc Assoc Am Physicians 1999, 111:22-34.
105. Neeck G., Crofford L.J. Neuroendocrine perturbations in fibromyalgia and chronic fatigue syndrome. Rheum Dis Clin North Am 2000, 26:989-1002.
106. Crofford L.J., Young E.A., Engleberg N.C., et al. Basal circadian and pulsatile ACTH and cortisol secretion in patients with fibromyalgia and/or chronic fatigue syndrome. Brain Behav Immun 2004, 18:314-325.
107. McClean S.A., Williams D.A., Stein P.K., et al. Cerebrospinal fluid corticotrophin-releasing factor concentration is associated with pain but not fatigue symptoms in patients with fibromyalgia. Neuropsychopharmacology 2006, 31:2776-2782.
108. McClean S.A., Williams D.A., Harris R.E., et al. Momentary relationship between cortisol secretion and symptoms in patients with fibromyalgia. Arthritis Rheum 2005, 52:3660-3669.
109. Bennett R.M., Clark S.R., Burckhardt C.S., et al. Hypothalamic-pituitary-insulin-like growth factor-I axis dysfunction in patients with fibromyalgia. J Rheumatol 1997, 24:1384-1389.
110. Neeck G., Riedel W. Thyroid function in patients with fibromyalgia syndrome. J Rheumatol 1992, 19:1120-1122.
111. Petzke F., Clauw D.J. Sympathetic nervous system function in fibromyalgia. Curr Rheumatol Rep 2000, 2:116-123.
112. Qiao Z.G., Vaeroy H., Morkrid L. Electrodermal and microcirculatory activity in patients with fibromyalgia during baseline, acoustic stimulation, and cold pressor tests. J Rheumatol 1991, 18:1383-1389.
113. Van Denderen J.C., Boersma J.W., Zeinstra P., et al. Physiological effects of exhaustive physical exercise in primary fibromyalgia syndrome (PFS): is PFS a disorder of neuroendocrine reactivity?. Scand J Rheumatol 1992, 21:35-37.
114. Bou-Holaigah I., Calkins H., Flynn J.A., et al. Provocation of hypotension and pain during upright tilt table testing in adults with fibromyalgia. Clin Exp Rheumatol 1997, 15:239-246.
115. Martinez-Lavin M., Hermosillo A.G., Mendoza C., et al. Orthostatic sympathetic derangement in subjects with fibromyalgia. J Rheumatol 1997, 24:714-718.
116. Raj S.R., Brouillard D., Simpson C.S., et al. Dysautonomia among patients with fibromyalgia: a noninvasive assessment. J Rheumatol 2000, 27:2660-2665.
117. Martinez-Lavin M. Biology and therapy of fibromyalgia. Stress, the stress response system, and fibromyalgia. Arthritis Res Ther 2007, 9:216.
118. Heim C., Newport D.J., Heit S., et al. Pituitary-adrenal and autonomic responses to stress in women after sexual and physical abuse in childhood. JAMA 2000, 284:592-597.
119. McBeth J., Silman A.J., Gupta A., et al. Moderation of psychosocial risk factors through dysfunction of the hypothalamic-pituitary-adrenal stress axis in the onset of chronic widespread musculoskeletal pain. Findings of a population-based prospective cohort study. Arthritis Rheum 2007, 56:360-371.
120. Holliday K.L., Nicholl B.I., Macfarlane G.J., et al. Genetic variation in the hypothalamic-pituitary-adrenal stress axis influences susceptibility to musculoskeletal pain: results from the EPIFUND study. Ann Rheum Dis 31 Aug 2009, [Online].
121. Korszun A., Young E.A., Engleberg N.C., et al. Follicular phase hypothalamic-pituitary-gonadal axis function in women with fibromyalgia and chronic fatigue syndrome. J Rheumatol 2000, 27:1526-1530.
122. Akkus S., Delibas N., Tamer M.N. Do sex hormones play a role in fibromyalgia?. Rheumatology 2000, 39:1161-1163.
123. Gur A., Cevik R., Sarac A.J., et al. Hypothalamic-pituitary-gonadal axis and cortisol in young women with primary fibromyalgia: the potential roles of depression, fatigue, and sleep disturbance in the occurrence of hypocortisolism. Ann Rheum Dis 2004, 63:1504-1506.
124. Okifuji A., Turk D.C. Sex hormones and pain in regularly menstruating women with fibromyalgia syndrome. J Pain 2006, 7:851-859.
125. Vamvakopoulos N.C., Chrousos G.P. Evidence of direct estrogenic regulation of human corticotropin-releasing hormone gene expression. Potential implications for the sexual dimorphism of the stress response and immune/inflammatory reaction. J Clin Invest 1993, 92:1896-1902.
126. Tsigos C., Chrousos G.P. Hypothalamic-pituitary-adrenal axis, neuroendocrine factors and stress. J Psychosom Res 2002, 53:865-871.
127. Waxman J., Zatzkis S.M. Fibromyalgia and menopause. Examination of the relationship. Postgrad Med 1986, 80:165-167. 170-1.
128. Dessein P.H., Shipton E.A., Stanwix A.E. Neuroendocrine deficiency-mediated development and persistence of pain in fibromyalgia: a promising paradigm?. Pain 2000, 86:213-215.
129. Lautenbacher S., Rollman G.B. Possible deficiencies of pain modulation in fibromyalgia. Clin J Pain 1997, 13:189-196.
130. Bennett R.M. Emerging concepts in the neurobiology of chronic pain: evidence of abnormal sensory processing in fibromyalgia. Mayo Clin Proc 1999, 74:385-398.
131. Staud R. Evidence of involvement of central neural mechanisms in generating fibromyalgia pain. Curr Rheumatol Rep 2002, 4:299-305.
132. Baranauskas G., Nistri A. Sensitization of pain pathways in the spinal cord: cellular mechanisms. Prog Neurobiol 1998, 54:349-365.
133. Woolf C.J. Pain: moving from symptom control toward mechanism-specific pharmacologic management. Ann Intern Med 2004, 140:441-451.
134. Latremoliere A., Woolf C.J. Central sensitization: a generator of pain hypersensitivity by central neural plasticity. J Pain 2009, 10:895-926.
135. Buskila D., Neumann L. Musculoskeletal injury as a trigger for fibromyalgia/posttraumatic fibromyalgia. Curr Rheumatol Rep 2000, 2:104-108.
136. Wallace D.J., Linker-Israeli M., Hallegua D., et al. Cytokines play an aetiopathogenetic role in fibromyalgia: a hypothesis and pilot study. Rheumatology 2001, 40:743-749.
137. Watkins L.R., Maier S.F. Immune regulation of central nervous system functions: from sickness responses to pathological pain. J Intern Med 2005, 257:139-155.
138. Vaeroy H., Helle R., Fokrre O., et al. Elevated CSF levels of substance P and high incidence of Raynaud phenomenon in patients with fibromyalgia: new features for diagnosis. Pain 1988, 32:21-26.
139. Russell I.J., Orr M.D., Littman B., et al. Elevated cerebrospinal fluid levels of substance P in patients with fibromyalgia syndrome. Arthritis Rheum 1994, 37:1593-1601.
140. Watkins L.R., Wiertelak E.P., Furness L.E., et al. Illness-induced hyperalgesia is mediated by spinal neuropeptides and excitatory amino acids. Brain Res 1994, 664:17-24.
141. Schwarz M.J., Spath M., Muller-Bardorff H., et al. Relationship of substance P, 5-hydroxyindole acetic acid and tryptophan in serum of fibromyalgia patients. Neurosci Lett 1999, 259:196-198.
142. Sarchielli P., Mancini M.L., Floridi A., et al. Increased levels of neurotrophins are not specific for chronic migraine: evidence from primary fibromyalgia syndrome. J Pain 2007, 8:737-745.
143. Harris R.E., Sundgren P.C., Pang Y., et al. Dynamic levels of glutamate within the insula are associated with improvements in multiple pain domains in fibromyalgia. Arthritis Rheum 2008, 58:903-907.
144. de Souza J.B., Potvin S., Goffaux P., et al. The deficit of pain inhibition in fibromyalgia is more pronounced in patients with comorbid depressive symptoms. Clin J Pain 2009, 25:123-127.
145. Russell I.J., Vaeroy H., Javors M., et al. Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis Rheum 1992, 35:550-556.
146. Russell I.J., Michalek J.E., Vipraio G.A., et al. Platelet 3H-imipramine uptake receptor density and serum serotonin levels in patients with fibromyalgia/fibrositis syndrome. J Rheumatol 1992, 19:104-109.
147. Yunus M.B., Dailey J.W., Aldag J.C., et al. Plasma tryptophan and other amino acids in primary fibromyalgia: a controlled study. J Rheumatol 1992, 19:90-94.
148. Basbaum A.I., Fields H.L. Endogenous pain control systems: brainstem pathways and endorphin circuitry. Annu Rev Neurosci 1984, 7:309-338.
149. Clark F.M., Proudfit H.K. The projections of noradrenergic neurons in the A5 catecholamine cell groups to the spinal cord in the rat: anatomical evidence that A5 neurons modulate nociception. Brain Res 1993, 616:200-213.
150. Kageyama K., Tozawa F., Horiba N., et al. Serotonin stimulates corticotropin-releasing factor gene expression in the hypothalamic paraventricular nucleus of conscious rats. Neurosci Lett 1998, 243:17-20.
151. Moldofsky H., Scarisbrick P. Induction of neurasthenic musculoskeletal pain syndrome by selective sleep stage deprivation. Psychosom Med 1975, 38:35-44.
152. Moldofsky H., Scarisbrick P., England R., et al. Musculoskeletal symptoms and non-REM sleep disturbance in patients with " fibrositis syndrome" and healthy subjects. Psychosom Med 1975, 37:341-351.
153. Nishizawa S., Benkelfat C., Young S.N., et al. Differences between males and females in rates of serotonin synthesis in human brain. Proc Natl Acad Sci U S A 1997, 94:5308-5313.
154. Gracely R.H., Petzke F., Wolf J.M., et al. Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia. Arthritis Rheum 2002, 46:1333-1343.
155. Bradley L.A., McKendree-Smith N.L., Alarcon G.S., et al. Is fibromyalgia a neurologic disease?. Curr Pain Headache Rep 2002, 6:106-114.
156. Fishbain D. Evidence-based data on pain relief with antidepressants. Ann Med 2000, 32:305-316.
157. Arnold L.M. Duloxetine and other antidepressants in the treatment of patients with fibromyalgia. Pain Med 2007, 8(Suppl 2):S63-S74.
158. Lawson K. Tricyclic antidepressants and fibromyalgia: what is the mechanism of action?. Expert Opin Investig Drugs 2002, 11:1437-1445.
159. Arnold L.M., Keck P.E., Welge J.A. Antidepressant treatment of fibromyalgia. A meta-analysis and review. Psychosomatics 2000, 41:104-113.
160. Tofferi J.K., Jackson J.L., OMalley P.G. Treatment of fibromyalgia with cyclobenzaprine: a meta-analysis. Arthritis Rheum 2004, 51:9-13.
161. Goldenberg D.L., Burckhardt C., Crofford L. Management of fibromyalgia syndrome. JAMA 2004, 292:2388-2395.
162. Beliles K., Stoudemire A. Psychopharmacologic treatment of depression in the medically ill. Psychosomatics 1998, 39:S2-19.
163. Nørregaard J., Volkmann H., Danneskiold-Samsø B. A randomized controlled trial of citalopram in the treatment of fibromyalgia. Pain 1995, 61:445-449.
164. Anderberg U.M., Marteinsdottir I., von Knorring L. Citalopram in patients with fibromyalgia - a randomized, double-blind, placebo-controlled study. Eur J Pain 2000, 4:27-35.
165. Wolfe F., Cathey M.A., Hawley D.J. A double-blind placebo controlled trial of fluoxetine in fibromyalgia. Scand J Rheumatol 1994, 23:255-259.
166. Goldenberg D., Mayskiy M., Mossey C., et al. A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis Rheum 1996, 39:1852-1859.
167. Arnold L.M., Hess E.V., Hudson J.I., et al. A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia. Am J Med 2002, 112:191-197.
168. Patkar A.A., Masand P.S., Krulewicz S., et al. A randomized, controlled trial of controlled release paroxetine in fibromyalgia. Am J Med 2007, 120:448-454.
169. Millan M.J. Descending control of pain. Prog Neurobiol 2002, 66:355-474.
170. Fishbain D.A., Cutler R., Rosomoff H.L., et al. Evidence-based data from animal and human experimental studies on pain relief with antidepressants: a structured review. Pain Med 2000, 1:310-316.
171. Harvey A.T., Rudolph R.L., Preskorn S.H. Evidence of the dual mechanisms of action of venlafaxine. Arch Gen Psychiatry 2000, 57:503-509.
172. Zijlstra TR, Barendregt PJ, van de Laar MAF. Venlafaxine in fibromyalgia: results of a randomized, placebo-controlled, double-blind trial. 66th Annual Meeting of the American College of Rheumatology, New Orleans, LA, October 24-29, 2002.
173. Bymaster F.P., Dreshfield-Ahmad L.J., Threlkeld P.G., et al. Comparative affinity of duloxetine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 2001, 25:871-880.
174. Eli Lilly and Company, Cymbalta (duloxetine), package insert. Indianapolis (IN), June 2008.
175. Arnold L.M., Lu Y., Crofford L.J., et al. A double-blind, multicenter trial comparing duloxetine to placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum 2004, 50:2974-2984.
176. Arnold L.M., Rosen A., Pritchett Y.L., et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 2005, 119:5-15.
177. Russell I.J., Mease P.J., Smith T.R., et al. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain 2008, 136:432-444.
178. Gahimer J., Wernicke J., Yalcin I., et al. A retrospective pooled analysis of duloxetine safety in 23,983 subjects. Curr Med Res Opin 2007, 23:175-184.
179. Greist J., McNamara R.K., Mallinckrodt C.H., et al. Incidence and duration of antidepressant-induced nausea: duloxetine compared with paroxetine and fluoxetine. Clin Ther 2004, 26:1446-1455.
180. Wernicke J.F., Lledo A., Raskin J., et al. An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies. Drug Saf 2007, 30:437-455.
181. Forest Pharmaceuticals, Inc. Savella (milnacipran), package insert. June 2009.
182. Gendreau R.M., Thorn M.D., Gendreau J.F., et al. Efficacy of milnacipran in patients with fibromyalgia. J Rheumatol 2005, 32:1975-1985.
183. Clauw D.J., Mease P., Palmer R.H., et al. Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clin Ther 2008, 30:1988-2004.
184. Mease P.J., Clauw D.J., Gendreau M., et al. The efficacy and safety of milnacipran for treatment of fibromyalgia. A randomized, double-blind, placebo-controlled trial. J Rheumatol 2009, 36:398-409.
185. Dooley D.J., Taylor C.P., Donevan S., et al. Ca2 channel α2δ ligands: novel modulators of neurotransmission. Trends Pharmacol Sci 2007, 28:75-82.
186. Field M.J., Cox P.J., Stott E., et al. Identification of the alpha2-delta-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin. Proc Natl Acad Sci U S A 2006, 103:17537-17542.
187. Taylor C.J., Angelotti T., Fauman E. Pharmacology and mechanism of action of pregabalin: the calcium channel α2-δ (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res 2007, 73:137-150.
188. Pfizer Inc, Lyrica (pregabalin), package insert. New York; June 2007.
189. Crofford L.J., Rowbotham M.C., Mease P.J., et al. Pregabalin for the treatment of fibromyalgia syndrome. Results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005, 52:1264-1273.
190. Mease P.J., Russell I.J., Arnold L.M., et al. A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol 2008, 35:502-514.
191. Arnold L.M., Russell I.J., Diri E.W., et al. A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain 2008, 9:792-805.
192. Crofford L.J., Mease P.J., Simpson S.L., et al. Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): a 6-month, double-blind, placebo-controlled trial with pregabalin. Pain 2008, 136:419-431.
193. Pfizer Inc, Neurontin (gabapentin), package insert. New York; January 2007.
194. Arnold L.M., Goldenberg D.L., Stanford S.B., et al. Gabapentin in the treatment of fibromyalgia. A randomized, double-blind, placebo-controlled, multicenter trial. Arthritis Rheum 2007, 56:1336-1344.
195. Rossy L.A., Buckelew S.P., Dorr N., et al. A meta-analysis of fibromyalgia treatment interventions. Ann Behav Med 1999, 21:180-191.
196. Goldenberg D.L., Felson D.T., Dinerman H. A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis Rheum 1986, 29:1371-1377.
197. Fossaluzza V., De Vita S. Combined therapy with cyclobenzaprine and ibuprofen in primary fibromyalgia syndrome. Int J Clin Pharmacol Res 1992, 12:99-102.
198. Clark S., Tindall E., Bennett R.M. A double blind crossover trial of prednisone versus placebo in the treatment of fibrositis. J Rheumatol 1985, 12:980-983.
199. Bennett R.M., Kamin M., Karim R., et al. Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. Am J Med 2003, 114:537-545.
200. Senay E.C., Adams E.H., Geller A., et al. Physical dependence on Ultram® (tramadol hydrochloride): both opioid-like and atypical withdrawal symptoms occur. Drug Alcohol Depend 2003, 69:233-241.
201. Kemple KL, Smith G, Wong-Ngan J. Opioid therapy in fibromyalgia - a four year prospective evaluation of therapy selection, efficacy, and predictors of outcome. Arthritis Rheum 2003;48:S88.
202. Wolfe F., Anderson J., Harkness D., et al. A prospective, longitudinal, multicenter study of service utilization and costs in fibromyalgia. Arthritis Rheum 1997, 40:1560-1570.
203. Bennett R.M., Jones J., Turk D.C., et al. An internet survey of 2,596 people with fibromyalgia. BMC Musculoskelet Disord 2007, 8:27.
204. Chu L.F., Clark D.J., Angst M.S. Opioid tolerance and hyperalgesia in chronic pain patients after one month of oral morphine therapy: a preliminary prospective study. J Pain 2006, 7:43-48.
205. King T., Gardell L.R., Wang R., et al. Role of NK-1 neurotransmission in opioid-induced hyperalgesia. Pain 2005, 116:276-288.
206. Drewes A.M., Andreasen A., Jennum P., et al. Zopiclone in the treatment of sleep abnormalities in fibromyalgia. Scand J Rheumatol 1991, 20:288-293.
207. Gronblad M., Nykanen J., Konttinen Y., et al. Effect of zopiclone on sleep quality, morning stiffness, widespread tenderness and pain and general discomfort in primary fibromyalgia patients. A double-blind randomized trial. Clin Rheumatol 1993, 12:186-191.
208. Moldofsky H., Lue F.A., Mously C., et al. The effect of zolpidem in patients with fibromyalgia: a dose ranging, double blind, placebo controlled, modified crossover study. J Rheumatol 1996, 23:529-533.
209. Russell I.J., Fletcher E.M., Michalek J.E., et al. Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam. A double-blind, placebo-controlled study. Arthritis Rheum 1991, 34:552-560.
210. Quijada-Carrera J., Valenzuela-Castano A., Povedano-Gomez J., et al. Comparison of tenoxicam and bromazepan in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. Pain 1996, 65:221-225.
211. Russell I.J., Perkins A.T., Michalek J.E. Sodium oxybate relieves pain and improves function in fibromyalgia syndrome: a randomized, double-blind, placebo-controlled, multicenter clinical trial. Arthritis Rheum 2009, 60:299-309.
212. Nicholson K.L., Balster R.L. GHB: a new and novel drug of abuse. Drug Alcohol Depend 2001, 63:1-22.
213. Griffiths R.R., Johnson M.W. Relative abuse liability of hypnotic drugs: a conceptual framework and algorithm for differentiating among compounds. J Clin Psychiatry 2005, 66(Suppl 9):31-41.
214. Busch A.J., Barber K.A., Overend T.J., et al. Exercise for treating fibromyalgia syndrome. Cochrane Database Syst Rev 2007, (4). CD003786.
215. Arnold L.M. Biology and therapy of fibromyalgia. New therapies in fibromyalgia. Arthritis Res Ther 2006, 8:212.
216. Clark S.R., Jones K.D., Burckhardt C.S., et al. Exercise for patients with fibromyalgia: risks versus benefits. Curr Rheumatol Rep 2001, 3:135-146.
217. Williams D.A., Cary M.A., Groner K.H., et al. Improving physical functional status in patients with fibromyalgia: a brief cognitive behavioral intervention. J Rheumatol 2002, 29:1280-1286.
218. Thieme K., Turk D.C., Flor H. Responder criteria for operant and cognitive-behavioral treatment of fibromyalgia syndrome. Arthritis Rheum 2007, 57:830-836.
219. Oliver K., Cronan T.A., Walen H.R., et al. Effects of social support and education on health care costs for patients with fibromyalgia. J Rheumatol 2001, 28:2711-2719.
220. King S.J., Wessel J., Bhambhani Y., et al. The effects of exercise and education, individually or combined, in women with fibromyalgia. J Rheumatol 2002, 29:2620-2627.
221. Rooks D.S., Gautam S., Romeling M., et al. Group exercise, education, and combination self-management in women with fibromyalgia: a randomized trial. Arch Intern Med 2007, 167:2192-2200.
222. Holdcraft L.C., Assefi N., Buchwald D. Complementary and alternative medicine in fibromyalgia and related syndromes. Best Pract Res Clin Rheumatol 2003, 17:667-683.
223. Mayhew E., Ernst E. Acupuncture for fibromyalgia-a systematic review of randomized clinical trials. Rheumatology (Oxford) 2007, 46:801-804.